肺癌是全球第二大常见癌症，会造成严重的身体和心理后果。在这篇叙述性综述中，我们探讨了运动作为辅助疗法的作用，以抵消人们在肺癌治疗前、治疗期间和治疗后经历的健康问题，并为运动处方和未来研究提供建议。叙述性基石综述。叙述性综述是旨在探讨运动在肺癌患者癌症护理中的作用。肺癌患者在治疗前、治疗期间和治疗后参加锻炼计划后，体质、力量和生活质量均得到改善。虽然在癌症治疗过程中通常会每周进行 2-5 次有氧运动（最大心率的 50-100%）和抗阻训练（最大重复次数的 50-85%）训练，但目前很少有肺癌患者能够获得运动服务。 “最佳”运动处方尚不清楚，但可能因人而异。当务之急是确定可耐受的起始运动剂量，肺癌及其治疗对呼吸系统的副作用，特别是呼吸短促（呼吸困难），可能会影响运动模式、持续时间和强度的初始最大阈值。迄今为止，对肺癌患者运动安全性的评估和报告很差——很少有试验报告这一点，但确实报告了少量严重不良事件。考虑当前证据基础的优势和局限性。版权所有 © 2024 作者。由爱思唯尔有限公司出版。保留所有权利。

Lung cancer is the second most common cancer diagnosed worldwide, resulting in significant physical and psychological consequences. In this narrative review, we explore the role of exercise as an adjunct therapy to counteract health issues experienced by people before, during and after treatment for lung cancer, and offer recommendations for exercise prescription and future research.Narrative cornerstone review.A narrative review was conducted to explore the role of exercise in cancer care for people diagnosed with lung cancer.Improvements in fitness, strength and quality of life have been demonstrated in people with lung cancer following participation in exercise programmes before, during and post treatment. Whilst combined aerobic (50-100 % heart rate maximum) and resistance (50-85 % of 1 repetition maximum) training, 2-5 times per week across the cancer continuum is typically prescribed, few people with lung cancer currently access exercise services. 'Optimal' exercise prescription is unclear, although is likely individual-specific. The immediate priority is to identify a tolerable starting exercise dosage, with the side effects of lung cancer and its treatment on the respiratory system, particularly shortness of breath (dyspnoea), likely driving the initial maximum threshold for session mode, duration and intensity. To date, exercise safety for people with lung cancer has been poorly evaluated and reported - few trials report it, but those that do report small numbers of serious adverse events.Recommendations for health professionals prescribing exercise therapy to people with lung cancer are provided, with consideration of the strengths and limitations of the current evidence base.Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.